thalidomide has been researched along with Blood Poisoning in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Rats were divided randomly into five groups: Sham group, LPS-treated sepsis group, LPS+thalidomide treated group, LPS+etanercept treated group and LPS+thalidomide+etanercept treated group, respectively." | 7.85 | Which one is more effective for the treatment of rat sepsis model: thalidomide or etanercept? ( Bardas, R; Gul, HF; Ilhan, N; Susam, S, 2017) |
| "Thalidomide is an inhibitor of tumour necrosis factor-alpha (TNFalpha) that has been proven effective for the treatment of experimental sepsis by Escherichia coli." | 7.73 | Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study. ( Bolanos, N; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Koussoulas, V; Laoutaris, G; Papadakis, V; Perrea, D, 2005) |
| "Thalidomide, an agent which inhibits biosynthesis of tumor necrosis factor alpha (TNF-alpha) and which is used to treat a variety of chronic inflammatory conditions, was investigated as therapy for experimental sepsis." | 7.72 | Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide. ( Dontas, I; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Kostomitsopoulos, N; Perrea, D; Poulaki, H, 2003) |
| "the thalidomide-alone treated mice showed 75% survival whereas 60% of the Augmentin-alone treated group survived." | 5.35 | A combination of thalidomide and augmentin protects BALB/c mice suffering from Klebsiella pneumoniae B5055-induced sepsis. ( Chhibber, S; Harjai, K; Kumar, V, 2009) |
| "The aim of this study was to evaluate the therapeutic effects of thalidomide and etanercept on lipopolysaccharide (LPS)-induced sepsis in a rat model." | 3.91 | The therapeutic effects of thalidomide and etanercept on septic rats exposed to lipopolysaccharide. ( Gül, HF; İlhan, N; Susam, S, 2019) |
| " Rats were divided randomly into five groups: Sham group, LPS-treated sepsis group, LPS+thalidomide treated group, LPS+etanercept treated group and LPS+thalidomide+etanercept treated group, respectively." | 3.85 | Which one is more effective for the treatment of rat sepsis model: thalidomide or etanercept? ( Bardas, R; Gul, HF; Ilhan, N; Susam, S, 2017) |
| "Thalidomide is an inhibitor of tumour necrosis factor-alpha (TNFalpha) that has been proven effective for the treatment of experimental sepsis by Escherichia coli." | 3.73 | Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study. ( Bolanos, N; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Koussoulas, V; Laoutaris, G; Papadakis, V; Perrea, D, 2005) |
| "Thalidomide, an agent which inhibits biosynthesis of tumor necrosis factor alpha (TNF-alpha) and which is used to treat a variety of chronic inflammatory conditions, was investigated as therapy for experimental sepsis." | 3.72 | Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide. ( Dontas, I; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Kostomitsopoulos, N; Perrea, D; Poulaki, H, 2003) |
| "the thalidomide-alone treated mice showed 75% survival whereas 60% of the Augmentin-alone treated group survived." | 1.35 | A combination of thalidomide and augmentin protects BALB/c mice suffering from Klebsiella pneumoniae B5055-induced sepsis. ( Chhibber, S; Harjai, K; Kumar, V, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ilhan, N | 4 |
| Susam, S | 2 |
| Gul, HF | 2 |
| Bardas, R | 1 |
| Kumar, V | 1 |
| Harjai, K | 1 |
| Chhibber, S | 1 |
| Sullivan, E | 1 |
| Hoyle, C | 1 |
| Lee, CK | 1 |
| Barlogie, B | 1 |
| Zangari, M | 1 |
| Fassas, A | 1 |
| Anaissie, E | 1 |
| Morris, C | 1 |
| Van Rhee, F | 1 |
| Cottler-Fox, M | 1 |
| Thertulien, R | 1 |
| Muwalla, F | 1 |
| Mazher, S | 1 |
| Badros, A | 1 |
| Tricot, G | 1 |
| Wölfler, A | 1 |
| Bauer, F | 1 |
| Zollner, G | 1 |
| Weber, K | 1 |
| Sill, H | 1 |
| Linkesch, W | 1 |
| Giamarellos-Bourboulis, EJ | 2 |
| Poulaki, H | 1 |
| Kostomitsopoulos, N | 1 |
| Dontas, I | 1 |
| Perrea, D | 2 |
| Karayannacos, PE | 2 |
| Giamarellou, H | 2 |
| Bolanos, N | 1 |
| Laoutaris, G | 1 |
| Papadakis, V | 1 |
| Koussoulas, V | 1 |
| Wiedemann, HR | 1 |
| Raza, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| (PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older[NCT01453088] | Phase 2 | 63 participants (Actual) | Interventional | 2010-06-24 | Terminated (stopped due to Lack of Accrual) | ||
| Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma[NCT01241708] | Phase 3 | 146 participants (Actual) | Interventional | 2010-04-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01453088)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 27 |
| Auto Transplant High Dose Melphalan+Bortezomib | 27 |
Progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib at 3 years (NCT01453088)
Timeframe: Participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 13 |
| Auto Transplant High Dose Melphalan+Bortezomib | 11 |
1 review available for thalidomide and Blood Poisoning
| Article | Year |
|---|---|
Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.
Topics: Arthritis, Rheumatoid; Crohn Disease; Etanercept; Humans; Immunoglobulin G; Myelodysplastic Syndrome | 2000 |
9 other studies available for thalidomide and Blood Poisoning
| Article | Year |
|---|---|
Which one is more effective for the treatment of rat sepsis model: thalidomide or etanercept?
Topics: Animals; Etanercept; Interleukin-1beta; Male; NF-kappa B; Random Allocation; Rats; Rats, Wistar; Sep | 2017 |
The therapeutic effects of thalidomide and etanercept on septic rats exposed to lipopolysaccharide.
Topics: Animals; Cytokines; Disease Models, Animal; Etanercept; Lipopolysaccharides; Liver; Male; Rats; Rats | 2019 |
A combination of thalidomide and augmentin protects BALB/c mice suffering from Klebsiella pneumoniae B5055-induced sepsis.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Drug Therapy, Combina | 2009 |
Calciphylaxis, occurring 10 weeks after hypercalcaemia, in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arterioles; Calciphylaxis; Chelation Therapy; Cyclop | 2011 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Fatal Outcome; Female; Humans; | 2003 |
Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide.
Topics: Animals; Bacteremia; Cytokines; Escherichia coli Infections; Female; Humans; Immunosuppressive Agent | 2003 |
Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.
Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Endotoxins; Interferon-gamma; | 2005 |
[Consequences of unexpected drug effects, beginning with contergan studies by pediatrists].
Topics: Abnormalities, Drug-Induced; Acrodynia; Bacterial Infections; Child; Child, Preschool; Chloramphenic | 1981 |